原发性高血压三种治疗方案的药物经济学评价

Pharmacoeconomic Evaluation of Essential Hypertension Treated by Three Pharmacotherapeutic Schemes

目的:评价三种治疗原发性高血压病方案的临床疗效及安全性,并考察其药物经济学效果,为临床用药提供参考。方法:将2010年6月～2011年6月我院就诊的原发性高血压患者165例,随机分成A、B、C组,A组给予替米沙坦40mg,联用吲达帕胺2.5mg,1次/d,口服;B组给予氢氯噻嗪25mg,联用依那普利10mg,1次/d;C组给予酒石酸美托洛尔25mg联用硝苯地平10mg,2次/d,口服;疗程为8周;观察临床疗效并计算成本-效果比。结果:三组治疗成本分别为94.61元、102.35元、148.96元,有效率分别为92.59%,89.29%,87.27%(P>0.05),成本-效果比分别为1.02,1.15,1.71,不良反应分别为7.41%,8.93%,10.91%(P>0.05)。结论:三组方案费用效果相当,但是氯沙坦与吲达帕胺联用方案更具优势。

Objtctive：To evaluate the clinical effects and safety of three pharmacotherapemic schemes,and then discuss the economics effects.Methods： 165 patients with essential hypertension were derided into 3 groups,Group A were treated with the combination of telmisartan and indatyamide：Group B were treated with the combination of hydrochtorothiazide and enalapril;Group C were treated with the combination of metoprolol tartrate and nifedipine,observe the clinical efficacy and caletdate the cost - effectiveness ratio betwoen the three groups.Results：The cost of treatment of the three groups were Group A 94.61,Group B 102.35,Group C 148.96;the effective ratess were Group A 92.59%,Group B 89.29%.Group C 87.27%（P〉0.05）;the cost- effectiveness rattos were GroupA 1.02,Group B t. 15,Group C 1.7t：incidence of adverse reactions were Group A 7.41%,Group B 8.93%,GroupC 10.91%（P〉0.05）.Conclusion：The three drugs cost are roughly same,but losartan combinated with indapamide has advantages.